Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody

Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Premier, Inc. to Divest Non-Healthcare GPO Operations for Approximately $800 Million in Cash
Premier, Inc. to Divest Non-Healthcare GPO Operations for Approximately $800 Million in Cash


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced that it has entered into a definitive agreement with OMNIA

LivaNova to Announce Second-Quarter 2023 Results
LivaNova to Announce Second-Quarter 2023 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m

LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study
LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study, “A P

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference:
Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference


Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf

New Study Shows That 84% of People With Diabetes Struggle With Mental Health1
New Study Shows That 84% of People With Diabetes Struggle With Mental Health1


As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc.

New Study Shows That 84% of People With Diabetes Struggle With Mental Health1
New Study Shows That 84% of People With Diabetes Struggle With Mental Health1


As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc.

NanoString Reports Inducement Grants Under Nasdaq Listing Rules
NanoString Reports Inducement Grants Under Nasdaq Listing Rules


NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity

EQS-News: Abivax stock included in MSCI Indexes
EQS-News: Abivax stock included in MSCI Indexes
EQS-News: Abivax stock included in MSCI Indexes
Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiencyhttps://www.cyansecurity.com/:
Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency


Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and

Dexcom to Host Investor Day on June 23, 2023
Dexcom to Host Investor Day on June 23, 2023


DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations

Dexcom to Host Investor Day on June 23, 2023
Dexcom to Host Investor Day on June 23, 2023


DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations

Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener LabsPhoto, wide shot, wide-angle lens, soft focus,  IT consulting firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-uhXP0RHYYxDepjmHeSp1K8bF.png?st=2023-05-07T15%3A26%3A44Z&se=2023-05-07T17%3A26%3A44Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-07T16%3A18%3A55Z&ske=2023-05-08T16%3A18%3A55Z&sks=b&skv=2021-08-06&sig=4pcJOd8aEI1799liUV13F4ElqO7e4RZy8sa1PEeeNZA%3D
Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs


Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions

EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
EQS-News: Abivax appoints Ida Hatoum as Chief People Officer
Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics
Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics


Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene

EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
EQS-News: ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Vistagen to Present at Jefferies 2023 Global Healthcare Conference
Vistagen to Present at Jefferies 2023 Global Healthcare Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system